Five-year follow-up study reveals the efficacy of OsseoSpeed implant

NewsGuard 100/100 Score

The five-year follow-up study was made by Dr. Steveling and co-workers at the Department of Oral and Maxillofacial Surgery at the Heidelberg University in Germany. The conclusion is that the OsseoSpeed implant shows very good results also in compromised sites when using an early loading protocol.

“The mean marginal bone level change reported was -0.03 millimeters after five years, which is extremely good,” says Dr. AnnaKarin Lundgren, Head of Scientific Management at Astra Tech Dental.

The OsseoSpeed surface characteristics and properties have been reviewed in numerous published articles revealing positive bone response. Results from the extensive OsseoSpeed clinical study program show good functionality, and predictable and maintained marginal bone levels with a mean marginal bone level reduction of 0.3 mm. The maintained marginal bone levels are also confirmed in prospective studies with three and five year results. There is no significant dip in Implant Stability Quotient values traditionally seen at implants 2-6 weeks after installation. This is interpreted as a continuous gain in osseointegration and stability. Published data shows that the OsseoSpeed implant can be safely used with reported survival rate between 94.5% to 100%, including the use of immediate loading protocol even in the atrophic edentulous maxilla, in sinus lifted maxillary posterior jaw sites, immediate installation in extraction sockets and implants placed in atrophied mandibles close to the nerve.

OsseoSpeed is one of four key features of the Astra Tech BioManagement Complex. The other three key features are Conical Seal Design, Connective Contour and MicroThread each of them with more than 17 years of clinical experience and documentation.

New data available —a comparative study on marginal bone level maintenance in implant treated patients recently published

The Astra Tech Implant System comes out as number one in a meta–analysis study on marginal bone level maintenance recently published early online by Clinical Implant Dentistry and Related Research.

At the EAO meeting in Warsaw 2008, Astra Tech presented unique data on marginal bone level maintenance for the Astra Tech Implant System and challenged the current standard norm for implant treatment success. Today, a year after the Astra Tech challenge, this recently published scientific study by Dr. Laurell and co-worker, presents comparative data of the three implant systems fulfilling the set study inclusion criteria, whereof Astra Tech Implant System was one.

The purpose of the study was to compile and compare data on marginal bone level changes between loading and five years of function for all implant systems currently on the market.

To be included in this meta-analysis the implant systems, in addition to being on the market, should have a minimum of two published prospective studies presenting radiographic data of marginal bone level at baseline as well as after five years.

The Astra Tech Implant System showed the best results with only -0.24 millimeters bone reduction after five years and had also the most consistent performance with a very limited variation between the mean values in the different studies.

“The result of this study proves that we were right when challenging the current standard norm. Hopefully the dental academic society will look into the data and set a new standard norm for implant treatment success. This will force less serious implant companies to perform and present solid, reliable documentation, all for the benefit of the patient. Only three implant systems met the criteria in the above study, but it is even more striking that 90% of all implant suppliers on the market are unable to show any clinical documentation whatsoever on their implant systems, ” says Dr. Björn Delin, Business Unit Director, Dental at Astra Tech in Sweden.

Expanded labeling claims for Astra Tech Implant System cleared by FDA in September 2009

The Astra Tech Implant System is designed to maintain the marginal bone support and is proven clinically to maintain marginal bone level (mean marginal bone reduction of only 0.3 mm over 5 years).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management